Immatics N.V. (IMTX)
NASDAQ: IMTX · Real-Time Price · USD
6.39
-0.13 (-1.99%)
At close: Nov 13, 2026, 4:00 PM EST
6.51
+0.12 (1.88%)
After-hours: Nov 13, 2026, 7:53 PM EST
Immatics Revenue
Immatics had revenue of 6.92M EUR in the quarter ending September 30, 2026, with 33.47% growth. This brings the company's total for the last twelve months to 43.44M, down -48.75% year-over-year. In the year 2025, Immatics had annual revenue of 48.27M, down -69.03%. That makes Immatics the 28,114th largest company in the world by revenue and 3,798th in the United States.
Revenue (ttm)
43.44M EUR
Revenue Growth
-48.75%
P/S Ratio
17.71
Revenue / Employee
61,705 EUR
Employees
704
Market Cap
873.45M USD
Revenue by Segment
- Moderna, United States 37.25M 77.2%
- Bristol-Myers Squibb (BMS), United States 11.02M 22.8%
Fiscal year ended Dec 31, 2025 See the full Immatics breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 48.27M | -107.57M | -69.03% |
| Dec 31, 2024 | 155.84M | 101.84M | 188.60% |
| Dec 31, 2023 | 54.00M | -118.83M | -68.76% |
| Dec 31, 2022 | 172.83M | 138.07M | 397.17% |
| Dec 31, 2021 | 34.76M | 3.51M | 11.23% |
| Dec 31, 2020 | 31.25M | 12.80M | 69.40% |
| Dec 31, 2019 | 18.45M | 14.68M | 389.36% |
| Dec 31, 2018 | 3.77M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| MeiraGTx Holdings | 401.91M |
| Pharming Group | 386.75M |
| Syndax Pharmaceuticals | 289.68M |
| Rigel Pharmaceuticals | 288.21M |
| City Therapeutics | 14.34M |
| Aktis Oncology | 12.39M |
| Inventiva | 2.81M |
| Odyssey Therapeutics | 99.00K |
IMTX News
- 2 days ago - Immatics price target lowered to $14 from $17 at BofA - TheFly
- 5 days ago - Immatics reports Q3 EPS (EUR 0.50) vs. (EUR 0.42) last year - TheFly
- 5 days ago - Immatics Announces Third Quarter 2026 Financial Results and Business Update - GlobeNewsWire
- 17 days ago - Immatics price target lowered to $21 from $25 at Mizuho - TheFly
- 21 days ago - Immatics announces updated trial data from Phase 1b study of IMA402 - TheFly
- 22 days ago - Immatics Presents Clinical Activity of IMA402 PRAME Bispecific and IMA203CD8 PRAME Cell Therapy across Advanced Solid Tumors in Two Oral Presentations at 2026 ESMO Annual Meeting - GlobeNewsWire
- 4 weeks ago - Immatics initiated with a Buy at Stifel - TheFly
- 2 months ago - Immatics price target lowered to $17 from $18 at Jefferies - TheFly